Non-T-cell depleted HLA haploidentical peripheral blood stem cell transplantation for hematological malignancies: report of 36 cases.
- Author:
Hai-long YUAN
1
;
Ling LI
;
Jian-hua QU
;
Bing-zhao WEN
;
Ming JIANG
;
Jian-ping HAO
;
Rong CHEN
;
Xin-hong GUO
;
Yasen HALIDA
;
Shan-zheng WANG
;
Ling-lu DING
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Child; Female; Follow-Up Studies; Graft vs Host Disease; prevention & control; HLA Antigens; genetics; immunology; Haploidy; Hematologic Neoplasms; therapy; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2009;30(2):82-86
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the clinical outcome of human leukocyte antigen (HLA) haploidentical peripheral blood stem cell transplantation (PBSCT) from related donors for hematological malignancies.
METHODSThirty-six patients with hematological malignancies, with a median age of 25 (11-48) years, were transplanted with PBSC from an HLA-haploidentical family donors: 7 were 1 locus mismatched and 29 were 2-3 loci mismatched. The recipients received myeloablative conditioning regimen, in combination with different immunosuppressants according to the degree of HLA disparity followed by non-T-cell depleted PBSCT. The median number of CD34+ cells were 11 (4.16-21.00) x 10(6)/kg.
RESULTSAll patients achieved sustained, full donor-type engraftment. Fifteen patients (41.7%) developed grade I-II aGVHD. Among 29 patients followed up more than 18 months, 17 (58.6%) developed cGVHD. There was no statistical difference in decrease and recovery of T, B and NK cell subsets after transplantation between HLA haploidentical group and HLA identical PBSCT group. The median follow-up duration was 15 (4 -69) months. Five patients (13.9% ) relapsed. The 2-year probability of leukemia-free survival (LFS) was 82.2%.
CONCLUSIONNon-T-cell depleted HLA-haploidentical PBSCT is safe and feasible for patients with hematological malignancies after myeloablative conditioning regimen combined with intensive immunosuppressants.
